Bonesupport Holding AB BONEX
Proprietary bio-ceramic platform compounds clinical differentiation and regulatory barriers into durable high-margin economics in bone repair.
Risk and Business model hold this up; Valuation is the soft spot.
| Moat | 7.0 |
| Management | 6.0 |
| Valuation | 4.0 |
| Risk · 10 = lowest | 8.0 |
| Business model | 8.0 |
| Optionality | 5.0 |
The price needs 23.0% growth a year for ten years. The AI thinks 18.0% is achievable, at a 22.0% margin.
The -5% gap shows the stock is modestly overvalued, as 18% achievable growth falls short of the 23% required at 22% margin to support the current price.
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally. The company offers CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; and CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also provides CERAMENT Bead Tray, an adjunctive local delivery option for surgeons desiring targeted delivery to osseous defects and for dead space management. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.
Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.
Start the thirty days · no card